Permeating the blood brain barrier and Abrogating the inflammation in stroke: Implications for stroke therapy

Current Pharmaceutical Design

Volumn 18, Issue 25, 2012, Pages 3670-3676

  Borlongan, Cesar V ^b   Glover, Loren E ^b   Sanberg, P R ^b   Hess, David C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Blood brain barrier; Cerebral palsy; Mannitol; Neurotrophic factor; NF kB; Stem cells; Transplantation

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MANNITOL; NERVE GROWTH FACTOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL ACTIVATION; COGNITION; CORD BLOOD STEM CELL TRANSPLANTATION; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TIGHT JUNCTION;

ANIMALS; BLOOD-BRAIN BARRIER; HUMANS; INFLAMMATION; MODELS, ANIMAL; STROKE;

EID: 84867535127     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802002841     Document Type: Review

References (56)

1. Blau H, Brazelton T, Keshet G, Rossi F. Something in the eye of the beholder. Science 2002; 298: 361-2.
2. Mezey E, Nagy A, Szalayova I, et al. Comment on Failure of bone marrow cells to transdifferentiate into neural cells in vivo. Science 2003; 299: 1184.
3. Theise ND, Krause DS, Sharkis S. Comment on little evidence for developmental plasticity of adult hematopoietic stem cells. Science 2003; 299: 1317.
4. Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults--United States, 1999. MMWR Morbidity and Mortality Weekly Report 2001; 50: 120-5.
5. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-7.
6. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 2002; 297: 2256-9.
7. Weimann JM, Charlton CA, Brazelton TR, Hackman RC, Blau HM. Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brains. Proc Natl Acad Sci USA 2003; 100: 2088-93.
8. Hess D, Borlongan C. Stem cells and neurological diseases. Cell Prolif 2008; 41: 94-114.
9. Borlongan CV, Tajima Y, Trojanowski JQ, Lee VMY, Sanberg PR. Transplantation of cryopreserved human embryonal carcinomaderived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol 1998; 149: 310-21.
10. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 574-7.
11. Vendrame M, Gemma C, Pennypacker KR, et al. Cord blood rescues stroke-induced changes in splenocyte phenotype and function. Exp Neurol 2006; 199: 191-200.
12. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke 2004; 35: 2385-9.
13. Yasuhara T, Hara K, Maki M, Xu L, Yu G, Ali M, et al. Mannitol facilitates neurotrophic factor up-regulation and behavioural recovery in neonatal hypoxic-ischaemic rats with human umbilical cord blood grafts. J Cell Mol Med 2010; 14: 914-21.
14. Hess DC, Howard E, Cheng C, Carroll J, Hill WD, Hsu CY. Hypertonic mannitol loading of NF-kappaB transcription factor decoys in human brain microvascular endothelial cells blocks upregulation of ICAM-1. Stroke 2000; 31: 1179-86.
15. Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 2011; [Epub ahead of print].
16. Blanchette M, Fortin D. Blood-brain barrier disruption in the treatment of brain tumors. Methods Mol Biol 2011; 686: 447-63.
17. Ferber D. Bridging the blood-brain barrier: New methods improve the odds of getting drugs to the brain cells that need them. PLoS Biol 2007; 5: e169.
18. Borlongan CV, Sanberg PR, Freeman TB. Neural transplantation for neurodegenerative disorders. Lancet 1999; 353 Suppl 1: S129-30.
19. Martin-Banderas L, A Holgado M, L Venero J, Alvarez-Fuentes J, Fernandez-Arevalo M. Nanostructures for Drug Delivery to the Brain. Curr Med Chem 2011; 18: 5303-21.
20. Stonestreet BS, Sadowska GB, Hanumara RC, Petrache M, Petersson KH, Patlak CS. Comparative effects of glucose-and mannitol-induced osmolar stress on blood-brain barrier function in ovine fetuses and lambs. J Cereb Blood Flow Metab 2011. [Epub ahead of print]
21. Park DH, Eve DJ, Musso III J, et al. Inflammation and stem cell migration to the injured brain in higher organisms. Stem Cells Dev 2009; 18: 693-702.
22. Rice III JE, Vannucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol 1981; 9: 131-41.
23. Okragly AJ, Haak-Frendscho M. An acid-treatment method for the enhanced detection of GDNF in biological samples. Exp Neurol 1997; 145: 592-6.
24. National Stroke Association [homepage on the Internet]. Centennial. CO: National Stroke Association [cited 2011 December 31]. Availible from: http://stroke.org.
25. Daar A, Bhatt A, Singer P. Stem cell research and transplantation: Science leading ethics. Transplant Proc 2004; 36: 2504-6.
26. Takagi Y, Nishimura M, Morizane A, et al. Survival and differentiation of neural progenitor cells derived from embryonic stem cells and transplanted into ischemic brain. J Neurosurg 2005; 103: 304-10.
27. Hess DC, Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother 2008; 8: 1193-201.
28. Newman MB, Davis CD, Borlongan CV, Emerich D, Sanberg PR. Transplantation of human umbilical cord blood cells in the repair of CNS diseases. Expert Opin Biol Ther 2004; 4: 121-30.
29. Vannucci RC, Vannucci SJ. Perinatal hypoxic-ischemic brain damage: evolution of an animal model. Dev Neurosci 2005; 27: 81-6.
30. Vannucci RC, Vannucci SJ. Cerebral carbohydrate metabolism during hypoglycemia and anoxia in newborn rats. Ann Neurol 1978; 4: 73-9.
31. Vannucci S, Vannucci R. Glycogen metabolism in neonatal rat brain during anoxia and recovery. J Neurochem 1980; 34: 1100-5.
32. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet 2005; 365: 663-70.
33. Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med 2005; 353: 1574-84.
34. Azzopardi DV, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009; 361: 1349-58.
35. Carroll JE, Borlongan CV. Adult stem cell therapy for acute brain injury in children. CNS Neurol Disord Drug Targets 2008; 7: 361-9.
36. Park DH, Lee JH, Borlongan CV, Sanberg PR, Chung YG, Cho TH. Transplantation of umbilical cord blood stem cells for treating spinal cord injury. Stem Cell Rev 2011; 7: 181-94.
37. Dabney KW, Lipton GE, Miller F. Cerebral palsy. Curr Opin Pediatr 1997; 9: 81-8.
38. Lequin MH, Barkovich AJ. Current concepts of cerebral malformation syndromes. Curr Opin Pediatr 1999; 11: 492-6.
39. Berger R, Garnier Y. Pathophysiology of perinatal brain damage. Brain Res Brain Res Rev 1999; 30: 107-34.
40. Damiano DL. Activity, activity, activity: rethinking our physical therapy approach to cerebral palsy. Phys Ther 2006; 86: 1534-40.
41. Hermansen MC, Hermansen MG. Perinatal infections and cerebral palsy. Clin Perinatol 2006; 315-33.
42. Lipson A, Gillerot Y, Tannenberg A, Giurgea S. Two cases of maternal antenatal splenic rupture and hypotension associated with Moebius syndrome and cerebral palsy in offspring. Further evidence for a utero placental vascular aetiology for the Moebius syndrome and some cases of cerebral palsy Eur J Pediatr 1996; 155: 800-4.
43. Spencer N, Devereux E, Wallace A, et al. Disabling conditions and registration for child abuse and neglect: a population-based study. Pediatrics 2005; 116: 609-13.
44. Yasuhara T, Matsukawa N, Yu G, Xu L, Mays RW, Kovach J, Deans RJ, Hess DC, Carroll JE, Borlongan CV. Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury. Cell Transplant 2006; 15: 231-8.
45. Ikeda M, Bhattacharjee AK, Kondoh T, Nagashima T, Tamaki N. Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening. Biochem Biophys Res Commun 2002; 291: 669-74.
46. Kriz J. Inflammation in ischemic brain injury: timing is important. Crit Rev Neurobiol 2006; 18: 145-57.
47. Emsley HC, Smith CJ, Tyrrell PJ, Hopkins SJ. Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit Care 2008; 9: 125-38.
48. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010; 129: 154-69.
49. Takano T, Oberheim NA, Cotrina ML, Nedergaard M. Astrocytes and ischemic injury. Stroke 2009; 40: S8-S12.
50. Borlongan CV, Weiss MD. Baby STEPS: a giant leap for cell therapy in neonatal brain injury. Pediatr Res 2011; 70: 3-9.
51. Clinical Trials [homepage on the internet]. Washington, D.C.: ClinicalTrials.gov [cited 2011 December 15]. Available from: http://clinicaltrials.gov.
52. Borlongan CV, Chopp M, Steinberg GK, et al. Potential of stem/progenitor cells in treating stroke: the missing steps in translating cell therapy from laboratory to clinic. Regen Med 2008; 3: 249-50.
53. Borlongan CV. Cell therapy for stroke. Stroke 2009; 40:s146-8.
54. Chopp M, Steinberg GK, Kondziolka D, et al. Who's in favor of translational cell therapy for stroke: STEPS Forward Please? Cell Transplant 2009; 18: 691-3.
55. Parolini O, Alviano F, Bergwerf I, et al. Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells Dev 2010; 19: 143-54.
56. Stem Cell Therapies as an Emerging Paradigm in Stroke Participants. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 2009; 40: 51.